Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
addressing, alpha, Amherst, anetumumab, aninter, Appeal, argument, brochure, BSP, charter, cohort, coltuximab, commonly, consummated, consummation, content, customary, cycle, deduction, dispensing, doubt, Fellow, forfeiture, Foundation, garner, Genzyme, graduate, heard, heavily, Hurricane, impute, indatuximab, indemnification, IPR, IRH, isatuximab, LIFO, lifted, marginally, mirvetuximab, monetization, monetized, myelodysplastic, nonclinical, nonproprietary, occupied, oral, overseeing, overseen, physician, PTAB, ravtansine, reaction, remitted, repaid, resume, retail, Richard, Sandra, soravtansine, stomach, Subtopic, suggesting, suspected, syndrome, synergistic, Takeda, threshold, USD, vitro, Worcester
Removed:
adenocarcinoma, adjuvant, Brooklyn, chronic, complexity, conditional, Cripto, Cytovance, Doctor, epithelial, experienced, expression, gastric, Idec, invasive, irrevocable, lymphocytic, MARIANNE, maturing, MD, multiplying, neoadjuvant, notified, notional, NSCLC, perry, profile, relation, represented, residual, Science, settle, showed, stand, sublessor, supplied, tolerability, write
Filing tables
Filing exhibits
Related press release
IMGN similar filings
Filing view
External links
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements (Form S-8 No. 333-170788, 333-185086, 333-75372, 333-75374, 333-138713, 333-147738, 333-155540 and 333-200432) of ImmunoGen Inc. of our reports dated August 27, 2015, with respect to the consolidated financial statements of ImmunoGen Inc. and the effectiveness of internal control over financial reporting of ImmunoGen Inc. included in this Annual Report (Form 10-K) of ImmunoGen Inc. for the year ended June 30, 2015.
/s/ Ernst & Young LLP
Boston, Massachusetts
August 27, 2015
Consent of Independent Registered Public Accounting Firm